Tiny chip in blood could spot cancer return sooner
NCT ID NCT03656835
Summary
This study is testing a new nanochip technology that analyzes blood samples to monitor how well treatment is working and to try to detect if cancer returns earlier in patients with diffuse large B-cell lymphoma. Researchers will collect blood from 73 patients at diagnosis, during chemotherapy, and during follow-up to see if the nanochip can find genetic markers that track with treatment response and relapse. The goal is to develop a better way to monitor this type of cancer without needing frequent scans or biopsies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.